Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 993

1.

TSLP Inhibitors for Asthma: Current Status and Future Prospects.

Matera MG, Rogliani P, Calzetta L, Cazzola M.

Drugs. 2020 Feb 20. doi: 10.1007/s40265-020-01273-4. [Epub ahead of print]

PMID:
32078149
2.

α1-Antitrypsin deficiency and chronic respiratory disorders.

Cazzola M, Stolz D, Rogliani P, Matera MG.

Eur Respir Rev. 2020 Feb 12;29(155). pii: 190073. doi: 10.1183/16000617.0073-2019. Print 2020 Mar 31. Review.

3.

Severe Asthma and Biological Therapy: When, Which, and for Whom.

Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M.

Pulm Ther. 2019 Dec 26. doi: 10.1007/s41030-019-00109-1. [Epub ahead of print] Review.

PMID:
32048241
4.

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Pulm Ther. 2019 Dec;5(2):117-126. doi: 10.1007/s41030-019-00102-8. Epub 2019 Nov 2. Review.

5.

Innovative Coatings Based On Peppermint Essential Oil on Titanium and Steel Substrates: Chemical and Mechanical Protection Ability.

Cazzola M, Ferraris S, Banche G, Gautier Di Confiengo G, Geobaldo F, Novara C, Spriano S.

Materials (Basel). 2020 Jan 22;13(3). pii: E516. doi: 10.3390/ma13030516.

6.

A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma.

Matera MG, Rinaldi B, Berardo C, Rinaldi M, Cazzola M.

Expert Opin Drug Metab Toxicol. 2020 Jan 30:1-6. doi: 10.1080/17425255.2020.1716730. [Epub ahead of print]

PMID:
31958237
7.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.

N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.

PMID:
31914241
8.

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.

Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P.

Pulm Pharmacol Ther. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883. Epub 2019 Dec 26.

9.

The future of bronchodilation: looking for new classes of bronchodilators.

Cazzola M, Rogliani P, Matera MG.

Eur Respir Rev. 2019 Dec 23;28(154). pii: 190095. doi: 10.1183/16000617.0095-2019. Print 2019 Dec 31. Review.

10.

Pharmacology and Therapeutics of Bronchodilators Revisited.

Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Review.

PMID:
31848208
11.

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.

Calverley PM, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2019 Dec 2;14:2733-2744. doi: 10.2147/COPD.S221852. eCollection 2019.

12.

Bioactive materials: In vitro investigation of different mechanisms of hydroxyapatite precipitation.

Ferraris S, Yamaguchi S, Barbani N, Cazzola M, Cristallini C, Miola M, Vernè E, Spriano S.

Acta Biomater. 2020 Jan 15;102:468-480. doi: 10.1016/j.actbio.2019.11.024. Epub 2019 Nov 14.

13.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2020 Feb;95(2):156-166. doi: 10.1002/ajh.25677. Epub 2019 Nov 29.

PMID:
31721282
14.

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.

Di Buduo CA, Abbonante V, Marty C, Moccia F, Rumi E, Pietra D, Soprano PM, Lim D, Cattaneo D, Iurlo A, Gianelli U, Barosi G, Rosti V, Plo I, Cazzola M, Balduini A.

Blood. 2020 Jan 9;135(2):133-144. doi: 10.1182/blood.2019001103.

PMID:
31697806
15.

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning.

Bridgford JL, Lee SM, Lee CMM, Guglielmelli P, Rumi E, Pietra D, Wilcox S, Chhabra Y, Rubin AF, Cazzola M, Vannucchi AM, Brooks AJ, Call ME, Call MJ.

Blood. 2020 Jan 23;135(4):287-292. doi: 10.1182/blood.2019002561.

PMID:
31697803
16.

Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.

Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, Malcovati L, Cazzola M, Ogawa S, Haferlach T, Yang H, Koeffler HP.

Am J Hematol. 2020 Feb;95(2):133-143. doi: 10.1002/ajh.25673. Epub 2019 Nov 18.

PMID:
31680297
17.

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L.

Br J Pharmacol. 2019 Oct 29. doi: 10.1111/bph.14909. [Epub ahead of print]

PMID:
31660611
18.

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

Calzetta L, Matera MG, Cazzola M, Rogliani P.

Adv Ther. 2019 Dec;36(12):3291-3298. doi: 10.1007/s12325-019-01119-w. Epub 2019 Oct 25.

19.

RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-seq.

Gu M, Zwiebel M, Ong SH, Boughton N, Nomdedeu J, Basheer F, Nannya Y, Quiros PM, Ogawa S, Cazzola M, Rad R, Butler AP, Vijayabaskar MS, Vassiliou G.

Haematologica. 2019 Oct 24. pii: haematol.2019.230821. doi: 10.3324/haematol.2019.230821. [Epub ahead of print]

20.

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.

Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.

Pulm Pharmacol Ther. 2019 Dec;59:101855. doi: 10.1016/j.pupt.2019.101855. Epub 2019 Oct 19.

PMID:
31639476
21.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2020 Jan;95(1):E1-E3. doi: 10.1002/ajh.25644. Epub 2019 Nov 1. No abstract available.

PMID:
31588594
22.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Dec;59:101841. doi: 10.1016/j.pupt.2019.101841. Epub 2019 Sep 11.

PMID:
31520718
23.

Pharmacological treatment and current controversies in COPD.

Cazzola M, Rogliani P, Stolz D, Matera MG.

F1000Res. 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019. Review.

24.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1. Review.

PMID:
31474120
25.

Ultra-LABAs for the treatment of asthma.

Cazzola M, Rogliani P, Matera MG.

Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12. Review.

PMID:
31425937
26.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408. Epub 2019 Sep 1.

PMID:
31422716
27.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

28.

Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Cazzola M, Puxeddu E, Ora J, Rogliani P.

Mol Diagn Ther. 2019 Oct;23(5):603-614. doi: 10.1007/s40291-019-00413-1. Review.

PMID:
31363933
29.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002
30.

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D.

Respir Med. 2019 Jul - Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.

PMID:
31228775
31.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

32.

Defining Maximum Ecological Potential for heavily modified lowland streams of Northern Italy.

Erba S, Terranova L, Cazzola M, Cason M, Buffagni A.

Sci Total Environ. 2019 Sep 20;684:196-206. doi: 10.1016/j.scitotenv.2019.05.348. Epub 2019 May 24.

PMID:
31153067
33.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27. Review.

PMID:
31147200
34.

Cytocompatible and Anti-bacterial Adhesion Nanotextured Titanium Oxide Layer on Titanium Surfaces for Dental and Orthopedic Implants.

Ferraris S, Cochis A, Cazzola M, Tortello M, Scalia A, Spriano S, Rimondini L.

Front Bioeng Biotechnol. 2019 May 9;7:103. doi: 10.3389/fbioe.2019.00103. eCollection 2019.

35.

Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

Matera MG, Calzetta L, Rogliani P, Cazzola M.

Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. Review.

PMID:
31136930
36.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

37.

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.

Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P.

Blood. 2019 Jun 27;133(26):2802-2808. doi: 10.1182/blood.2018879536. Epub 2019 May 10. No abstract available.

PMID:
31076447
38.

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R.

Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub 2019 May 7.

39.

Response.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 May;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028. No abstract available.

PMID:
31060694
40.

Bronchodilators in subjects with asthma-related comorbidities.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Respir Med. 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001. Epub 2019 Apr 3. Review.

PMID:
31047116
41.

Cardiovascular Disease in Chronic Respiratory Disorders and Beyond.

Rogliani P, Cazzola M, Calzetta L.

J Am Coll Cardiol. 2019 May 7;73(17):2178-2180. doi: 10.1016/j.jacc.2018.11.068. No abstract available.

PMID:
31047005
42.

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.

Rumi E, Zibellini S, Boveri E, Cavalloni C, Riboni R, Casetti IC, Ciboddo M, Trotti C, Favaron C, Pietra D, Candido C, Ferretti VV, Cazzola M, Arcaini L.

Am J Hematol. 2019 Jul;94(7):E185-E188. doi: 10.1002/ajh.25489. Epub 2019 May 1. No abstract available.

PMID:
30972817
43.

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.

Bono E, McLornan D, Travaglino E, Gandhi S, Gallì A, Khan AA, Kulasekararaj AG, Boveri E, Raj K, Elena C, Ireland RM, Bianchessi A, Jiang J, Todisco G, Ferretti VV, Cazzola M, Marsh JCW, Malcovati L, Mufti GJ.

Leukemia. 2019 Oct;33(10):2495-2505. doi: 10.1038/s41375-019-0457-1. Epub 2019 Apr 2.

PMID:
30940907
44.

Clonal monocytosis of clinical significance.

Cazzola M.

Blood. 2019 Mar 21;133(12):1271-1272. doi: 10.1182/blood-2019-01-896084. No abstract available.

PMID:
30898774
45.

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG.

Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.

PMID:
30876907
46.

Introduction to a review series on transfusion medicine.

Cazzola M.

Blood. 2019 Apr 25;133(17):1793-1794. doi: 10.1182/blood-2019-01-888248. Epub 2019 Feb 26. No abstract available.

PMID:
30808640
47.

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J.

Expert Opin Pharmacother. 2019 Apr;20(6):737-750. doi: 10.1080/14656566.2019.1570133. Epub 2019 Feb 1. Review.

PMID:
30707637
48.

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17. Review.

PMID:
30660781
49.

Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.

Cazzola M, Page C, Calzetta L, Matera MG.

Pharm Pat Anal. 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030. Epub 2019 Jan 18.

PMID:
30657422
50.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

Supplemental Content

Loading ...
Support Center